Mr. Lam is responsible for the creation, implementation and management of the CMS’s development and growth strategy. Mr. Lam has clinician experience and deep understanding and knowledge of China‘s pharmaceutical industry, possessing unique insight and extensive experience in R&D, marketing, promotion, sales and other value-added services. He received his bachelor’s degree in clinical medicine from Zhanjiang Medical College in 1986, which was renamed Guangdong Medical University. Mr.Lam is a member of the Nomination Committee of the Company.
Mr. Chen has been re-designated as a non-executive Director with effect from 15 August 2024, and currently appointed as a senior consultant of CMS. Mr. Chen was the Chief Operating Officer and Vice-president of the Group, and appointed as an executive Director from December 2006 to August 2024. He joined the Group in 1995, was responsible for the business operation of the Group, including marketing, promotion, supply chain management, product manufacturing management and human resources management, etc. Mr. Chen possesses extensive experience in business operations of pharmaceutical companies and corporate management. Mr. Chen had acquired about four years’ experience as a public hospital doctor with Nanjing Drum Tower Hospital from 1990 to 1994. He received his bachelor’s degree in clinical medicine from Nanjing Medical College in 1990, which was subsequently renamed as Nanjing Medical University.
Ms. Chen joined CMS in 1995 and has remained with the Group since then. Ms. Chen is responsible for the Group’s finance, accounting, investor relations, government affairs and administration management. She holds an EMBA degree and is a senior accountant with extensive experience in financial management, fund raising, auditing and investor relations, etc. As at the end of the year 2022, Ms. Chen was awarded eight times the “Best CFO” in Healthcare and Pharmaceuticals by the Institutional Investor Magazine. Ms. Chen is the chairman of the Environmental, Social and Governance Committee of the Company.
Mr. Leung was appointed as an independent non-executive Director on 13 December 2017. Mr. Leung became a practicing lawyer since 1991 and was the chief representative of Woo Kwan Lee & Lo Beijing Office. He is currently a partner of Woo Kwan Lee & Lo. Mr. Leung is familiar with corporate finance, M&A and IPO legal services and has been involved in various listing and acquisition transactions of Chinese H-share companies and red chip companies. Mr. Leung is currently a China-Appointed Attesting Officer appointed by the Ministry of Justice of the PRC. Mr. Leung was an independent non-executive director of China Coal Energy Company Limited (a company listed on the Stock Exchange with stock code: 01898) from June 2017 to March 2023, China Communications Construction Company Limited (a company listed on the Stock Exchange with stock code: 01800) from January 2011 to November 2017 and China National Materials Company Limited […]
Ms. Luo was appointed as an independent non-executive Director on 31 March 2020. Ms. Luo has 28 years of investment experience. She currently works as an investment director of GL China Equity HK Management Limited and previously has worked as a consultant of GL China Equity HK Management Limited and a consultant of GL Capital Management Limited. Ms. Luo is an independent non- executive director of Central China New Life Limited (a company listed on the Stock Exchange with stock code: 09983) and Tianjin Port Development Holdings Limited (a company listed on the Stock Exchange with stock code: 03382). Ms. Luo was a managing director and head of Hong Kong China Equities at Barings Asset Management (Asia) Limited from 2013 to 2019. Her overall responsibilities included managing a team of investment managers and research analysts, as well as managing a range of Hong Kong and China equity strategies, including Barings’ […]
Mr. Fung was appointed as an independent non-executive Director on 6 October 2021. Mr. Fung has 10 years of experience in auditing, accounting and business advisory and has over 18 years of experience in managing finance and accounting functions, mergers and acquisitions, fund raising and investor relations for PRC companies listed in Hong Kong. Mr. Fung is currently serving as the chief financial officer of Chow Tai Fook Enterprises Limited. Mr. Fung worked in PricewaterhouseCoopers between 1994 and 2004, and he served as the chief financial officer and secretary to the board of directors of Baoye Group Company Limited (a company listed on the Stock Exchange with stock code: 02355) between 2004 and 2010. Mr. Fung served as the chief financial officer and company secretary of Greentown China Holdings Limited (a company listed on the Stock Exchange with stock code: 03900) between 2010 and 2019. Mr. Fung worked for Logan […]
